Red and green color intensities represented the relative increase and decrease in metabolite regulation, respectively (Fig
Beyond the Scale: Measuring What Matters What you weigh in on the scale is just a number
METHODS A PRISMA-guided systematic review (Figure 1) was performed using PubMed and MEDLINE databases, employing search terms "glutathione" AND "topical" AND "skin" OR "dermatology," yielding 446 articles with no time restriction
ADVANTAGES & DISADVANTAGES OF TREATMENT OPTIONS CVD: Cardiovascular Death Management of Type 2 Diabetes American Diabetes Assn 2020 Update Based upon recent research findings, the American Diabetes Asson & Europiean Asson for the Study of Diabetes recently updated their consensus treatment recommendations (Buse et al, 2019) for the following subsets of patients with diabetes: High risk diabetic patients GLP-1 agonists & SGLT2 inhibitors to reduce CV & renal risk in high risk patients, without regard to patient HbA1c levels (baseline or target) High risk for atherosclerotic CV disease GLP-1 agonists GLP-1 agonists produce the greatest benefit against CV events Systolic heart failure (HFrEF) & chronic kidney disease (CKD) SGLT2 inhibitors SGLT2 inhibitors have the greatest benefit to prevent progression of CKD, reduce hospitalization for HF, and reduce CV events & CV death Patients with foot ulcers SGLT2 inhibitors a recommended treatment, after consideration of risk vs benefits 2021 ADA Treatment Guidelines Figure 10
Growth hormone secretagogues are not appropriate for people with active cancer or a history of hormone-sensitive tumors, as GH can stimulate cell division broadly
Who is an ideal candidate for glutathione IV therapy
